Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

346 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The impact of a See and Treat Clinic on skin cancer treatment time.
Nolan K, O'Donnell K, Moloney FJ, Kelly CM, Potter S. Nolan K, et al. Among authors: kelly cm. J Plast Reconstr Aesthet Surg. 2022 Feb;75(2):893-939. doi: 10.1016/j.bjps.2021.11.038. Epub 2021 Nov 16. J Plast Reconstr Aesthet Surg. 2022. PMID: 34840112 No abstract available.
Vismodegib in the treatment of advanced BCC.
O'Kane GM, Lyons T, McDonald I, Mulligan N, Moloney FJ, Murray D, Kelly CM. O'Kane GM, et al. Among authors: kelly cm. Ir Med J. 2014 Jul-Aug;107(7):215-6. Ir Med J. 2014. PMID: 25226719
Real-World Analysis of the Clinical and Economic Impact of the 21-Gene Recurrence Score (RS) in Invasive Lobular Early-Stage Breast Carcinoma in Ireland.
McSorley LM, Tharmabala M, Al Rahbi F, Keane F, Evoy D, Geraghty JG, Rothwell J, McCartan DP, Greally M, O'Connor M, O'Mahony D, Keane M, Kennedy MJ, O'Reilly S, Millen SJ, Crown JP, Kelly CM, Prichard RS, Quinn CM, Walshe JM. McSorley LM, et al. Among authors: kelly cm. Curr Oncol. 2024 Mar 1;31(3):1302-1310. doi: 10.3390/curroncol31030098. Curr Oncol. 2024. PMID: 38534931 Free PMC article.
Multimodal, Technology-Assisted Intervention for the Management of Menopause after Cancer Improves Cancer-Related Quality of Life-Results from the Menopause after Cancer (Mac) Study.
Donohoe F, O'Meara Y, Roberts A, Comerford L, Valcheva I, Kearns U, Galligan M, Higgins MJ, Henry AL, Kelly CM, Walshe JM, Hickey M, Brennan DJ. Donohoe F, et al. Among authors: kelly cm. Cancers (Basel). 2024 Mar 12;16(6):1127. doi: 10.3390/cancers16061127. Cancers (Basel). 2024. PMID: 38539462 Free PMC article.
Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX® testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancer.
Browne IM, McLaughlin RA, Weadick CS, O'Sullivan S, McSorley LM, Hadi DK, Millen SJ, Higgins MJ, Crown JP, Prichard RS, McCartan DP, Hill AD, Connolly RM, Noonan SA, O'Mahony D, Murray C, O'Hanlon-Brown C, Hennessy BT, Quinn CM, Kelly CM, O'Reilly S, Morris PG, Walshe JM. Browne IM, et al. Among authors: kelly cm. Breast Cancer Res Treat. 2024 Oct 4. doi: 10.1007/s10549-024-07486-5. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 39365509
Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial.
Tibau A, Martínez MT, Ramos M, De La Cruz-Merino L, Santaballa A, O'Connor M, Martínez-Jañez N, Moreno F, Fernández I, Virizuela JA, Alarcón J, de La Haba-Rodríguez J, Sánchez-Rovira P, Albacar CR, Bueno Muiño C, Kelly C, Casas M, Bezares S, Rosell L, Albanell J. Tibau A, et al. Ther Adv Med Oncol. 2023 Jan 19;15:17588359221148921. doi: 10.1177/17588359221148921. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 36743520 Free PMC article.
Psilocybin and Hallucinogenic Mushrooms.
Fradet M, Kelly CM, Donnelly AJ, Suppes T. Fradet M, et al. Among authors: kelly cm. CNS Spectr. 2025 Jan 10:1-62. doi: 10.1017/S1092852924002487. Online ahead of print. CNS Spectr. 2025. PMID: 39789676 Review. No abstract available.
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)].
de Azambuja E, Piccart-Gebhart M, Fielding S, Townend J, Hillman DW, Colleoni M, Roylance R, Kelly CM, Lombard J, El-Abed S, Choudhury A, Korde L, Vicente M, Chumsri S, Rodeheffer R, Ellard SL, Wolff AC, Holtschmidt J, Lang I, Untch M, Boyle F, Xu B, Werutsky G, Tujakowski J, Huang CS, Baruch NB, Bliss J, Ferro A, Gralow J, Kim SB, Kroep JR, Krop I, Kuemmel S, McConnell R, Moscetti L, Knop AS, van Duijnhoven F, Gomez H, Cameron D, Di Cosimo S, Gelber RD, Moreno-Aspitia A. de Azambuja E, et al. Among authors: kelly cm. ESMO Open. 2024 Nov;9(11):103938. doi: 10.1016/j.esmoop.2024.103938. Epub 2024 Oct 17. ESMO Open. 2024. PMID: 39418883 Free PMC article. Clinical Trial.
346 results